GlassScriptPhysician profile
Edward A Lebrija
NPI 1932112000
$39,766.90
in general payments reported to CMS, 2019-2025
18 companies · $2,620 in 2025
The $2,620 reported for 2025 was more than what 88% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,072 · 2020: $9,463 · 2021: $7,670 · 2022: $6,758 · 2023: $4,399 · 2024: $785 · 2025: $2,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,419 · Food and Beverage: $1,555 · Royalty Or License: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,418.75 |
| Food and Beverage | $1,554.76 |
| Royalty Or License | $829.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $18,131.71 | 2019-2024 | |
| Gramercy Extremity Orthopedics LLC | $15,052.04 | 2020-2025 | |
| Stryker Corporation | $2,701.20 | 2022-2025 | Actishield, Salvation, 7 X 23mm Citrelock Implant |
| Arthrex, INC. | $2,092.65 | 2019 | |
| Integra Lifesciences Corporation | $378.99 | 2019-2020 | |
| Smith+Nephew, INC. | $322.23 | 2019-2025 | Pico, Pico 7, Renasys Go V2 Home |
| Organogenesis INC. | $300.04 | 2019-2024 | Puraply |
| Depuy Synthes Sales INC. | $264.60 | 2019-2023 | Hammerlock, Na |
| Averitas Pharma INC. | $118.01 | 2023-2025 | Qutenza |
| Acera Surgical, INC. | $96.66 | 2025 | Restrata Wound Matrix |
| Kerecis Limited | $87.97 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Polynovo North America LLC | $66.55 | 2023 | |
| Crossroads Orthopedics, LLC | $46.04 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $38.31 | 2022 | |
| Osiris Therapeutics INC. | $29.07 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $15.32 | 2024 | Snap, Activ.A.C., 3m Cavilon |
| Pacira Pharmaceuticals Incorporated | $14.68 | 2021 | |
| Acumed LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lebrija listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.